Dr. Jacqueline Lui, President of Eagle IP Limited, gave a talk titled “IP Protection Strategies for Drugs” at the Hong Kong Productivity Council for the forum “如何利用防偽技術保護藥品商標及品牌研討會(II)”.
我們過去活動
Recommended Insights
Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement
2024年1月9日Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]
閱讀更多 >
Patent Eligibility for Software in China
2022年4月4日Technology has progressed significantly since the early days of patent law, when US lawmakers in 1952 could only envision patentable subject matter into categories like “process, machine, manufacture, or composition of matter.” The recent explosion of new types of innovations that don’t fall neatly into these categories has resulted in a game of catch-up, where […]
閱讀更多 >
China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results
2022年6月30日China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
閱讀更多 >
AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines
2019年11月21日Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]
閱讀更多 >